openPR Logo
Press release

Schizophrenia Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2032, as per DelveInsight

04-25-2024 03:12 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Schizophrenia Market

Schizophrenia Market

"The Schizophrenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Schizophrenia pipeline products will significantly revolutionize the Schizophrenia market dynamics"

Key Takeaways from the Schizophrenia Market Research Report
• In the year 2021, the total Schizophrenia prevalent cases were 6.27 million in the 7MM which are expected to grow during the study period, i.e., 2019-2032.
• The highest number of total Schizophrenia prevalent cases among the EU5 countries was observed in Germany with 0.61 million cases in 2021 which are expected to grow during the study period, i.e., 2019-2032.
• The leading companies working in the Schizophrenia Market include Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others.
• Promising Schizophrenia Pipeline Therapies in the various stages of development include Brexpiprazole (OPC-34712), Aripiprazole, Cariprazine, Xanomeline and Trospium Chloride Capsules, CTP-692, and others.
• April 2024:- Karuna Therapeutics- A Phase 3, Multicenter, Two-part Study With a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) Followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia.
• March 2024:- Click Therapeutics Inc.- A Multicenter, Exploratory, Randomized, Double-Arm, 4-week Study to Evaluate the Overall Effects of Treatment With Abbreviated CT-156 in People With Schizophrenia.

Discover more about therapies set to grab major Schizophrenia Market Share @ Schizophrenia Market Size- https://www.delveinsight.com/report-store/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Schizophrenia Overview
Schizophrenia is a severe mental disorder in which people interpret reality abnormally. It may result in hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning and can be disabling. Contrary to public perception, schizophrenia is not a split or multiple personalities.

Schizophrenia Epidemiology Segmentation in the 7MM
• Total Schizophrenia Prevalent Cases
• Total Schizophrenia Diagnosed Cases
• Schizophrenia Gender-specific Cases
• Schizophrenia Severity-specific Cases
• Schizophrenia Age-specific Treated Cases
• Total Schizophrenia Treated Cases

Download the report to understand which factors are driving Schizophrenia Epidemiology Trends @ Schizophrenia Epidemiological Insights- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Schizophrenia Market Outlook
With no cure for schizophrenia, the main goals of schizophrenia treatment include symptom targeting and prevention of relapsed cases. Schizophrenia requires lifelong treatment, even when symptoms have subsided. Treatment with medications and psychosocial therapy can help manage the condition. In some cases, hospitalization may be needed. Pharmacological therapy plays a vital role in treating this disease, where many mono and combination pharmacological therapies are available for treating schizophrenia symptoms. Antipsychotics are the first choice among psychotropic agents used to treat schizophrenia.

Schizophrenia Treatment Market
The schizophrenia treatment options include medication (antipsychotics), psychological counseling and social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT). Currently available antipsychotics, which are thought to work primarily via modulation of dopamine, largely target positive symptoms. As a result, many patients are left with residual negative and cognitive symptoms. New research combined with an increased understanding of the etiology and pathophysiology of schizophrenia is leading to the development of novel agents to improve schizophrenia management and address the above-mentioned gaps.

To know more about Schizophrenia Treatment options, visit @ Schizophrenia Drugs- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Schizophrenia Emerging Drugs
• Ulotaront: Otsuka Pharmaceutical
• Luvadaxistat: Takeda
• CY6463: Cyclerion Therapeutics
• AVP 786: Avanir Pharmaceuticals

Schizophrenia Drugs Market
The global schizophrenia drugs market has witnessed substantial growth in recent years, primarily due to increased awareness, improved diagnostic techniques, and research and development in pharmaceuticals. The Schizophrenia market encompasses a wide array of antipsychotic drugs, aiming to target the root causes of schizophrenia symptoms.

Learn more about the Schizophrenia Pipeline Therapies in clinical trials @ Schizophrenia Market Landscape- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Schizophrenia Market Research Report
• Coverage- 7MM
• Study Period- 2019-2032
• Schizophrenia Companies- Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion/PsychoGenics, Otsuka Pharmaceuticals, Neurocrine Biosciences, Takeda, Minerva Neurosciences, Newron Pharmaceuticals, Lyndra Therapeutics, Pharmaceuticals Laboratories, Cerevel Therapeutics, and others.
• Schizophrenia Pipeline Therapies- Brexpiprazole (OPC-34712), Aripiprazole, Cariprazine, Xanomeline and Trospium Chloride Capsules, CTP-692, and others.
• Schizophrenia Market Dynamics: Schizophrenia Market Drivers and Barriers
• Schizophrenia Market Access and Reimbursement, Unmet Needs, and Future Perspectives

Discover more about Schizophrenia Drugs in development @ Schizophrenia Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Schizophrenia Market Overview at a Glance
4. Executive Summary of Schizophrenia
5. Epidemiology and Market Methodology
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. Patient Journey
9. Key Endpoints in Schizophrenia Clinical Trials
10. Marketed Therapies
11. Emerging Therapies
12. Conjoint Analysis
13. Schizophrenia: 7 Major Market Analysis
14. Market Access and Reimbursement
15. KOL Views
16. SWOT Analysis
17. Unmet Needs
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Important Links-
http://demo.advised360.com/read-blog/154799
https://thehealthbridges.com/read-blog/19127
https://app.talkshoe.com/user/joneswilliam/about#google_vignette
https://www.vaca-ps.org/blogs/142022/The-Evolving-Landscape-of-Healthcare-Business-Consulting-Services
https://www.anobii.com/en/01d38d0b9694756e64/profile/activity
https://myanimelist.net/profile/dennydonesgerman
https://forum.pivx.org/threads/healthcare-business-consulting-services-navigating-complexity-in-modern-healthcare.2035/
https://pubhtml5.com/homepage/npvs/
https://b31.org.uk/author/anniesmith9/
https://fairygodboss.com/users/profile/Ix-vMa09gj/Annie-Smith
https://forum.completefrance.com/index.php?/topic/71194-key-areas-of-focus-in-healthcare-consulting-services/
https://educatorpages.com/site/kelleadvin/pages/blog?
https://offgridworld.com/author/anniejones9/
https://www.openhumans.org/member/me/
https://findpenguins.com/5zphebtv0zouo
http://jobs.emiogp.com/author/williamsmith9/
https://www.shippingexplorer.net/en/user/williamsmith9/88249
https://wakelet.com/@DennyDones813
https://startupxplore.com/en/person/denny-dones
https://www.nfpjobs.com.au/employers/1939365-delveinsight
https://community.hodinkee.com/members/dennydoness
https://jobs.mikeroweworks.org/employers/1930150-delveinsight
https://www.social-vape.com/read-blog/132516
https://codex.core77.com/users/dennydones9
https://www.newjerseyhunter.com/members/dennydones1.84566/#about
https://au.blurb.com/user/dennydones9?profile_preview=true
https://trabajo.merca20.com/author/kelleadvin/
https://www.atlasobscura.com/users/dennydones1
https://www.mixcloud.com/dennydones1/
https://www.designspiration.com/ybhardwaj/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Schizophrenia Market is Expected to Showcase a Significant Growth at a CAGR of X% by 2032, as per DelveInsight here

News-ID: 3475586 • Views:

More Releases from DelveInsight Business Research LLP

Addison's Disease Market Outlook Report 2032 |Akorn Operating Co., Amneal Pharmaceuticals Inc., Bristol Myers Squibb Co., Neurocrine Biosciences Inc., Hikma Pharmaceuticals Plc., Merck & Co., Novartis AG., Pfizer Inc
Addison's Disease Market Outlook Report 2032 |Akorn Operating Co., Amneal Pharma …
DelveInsight's "Addison's Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Addison's Disease, historical and forecasted epidemiology as well as the Addison's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Addison's Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Addison's Disease market size
Anemia In Chronic Kidney Disease Market Outlook Report 2032 | 3SBio, UBI Pharma and Disc Medicine
Anemia In Chronic Kidney Disease Market Outlook Report 2032 | 3SBio, UBI Pharma …
DelveInsight's "Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Anemia In Chronic Kidney Disease, historical and forecasted epidemiology as well as the Anemia In Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Anemia In Chronic Kidney Disease market report provides current treatment practices, emerging drugs, the market share of
Visceral Pain associated with GI disorders Market Outlook Report 2032 | Addex Therapeutics Ltd., AstraZeneca., Astellas Pharma, Allergan, Chromocell Corporation, Takeda, GIcare Pharma, AbbVie, Grunenthal GmbH
Visceral Pain associated with GI disorders Market Outlook Report 2032 | Addex Th …
DelveInsight's "Visceral Pain associated with GI disorders Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Visceral Pain associated with GI disorders, historical and forecasted epidemiology as well as the Visceral Pain associated with GI disorders market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Visceral Pain associated with GI disorders market report provides current treatment practices, emerging drugs,
Glabellar Frown Lines Market Report Outlook 2032 | Allergan, Galderma, Merz Pharmaceuticals, Evolus, Revance Therapeutics, Hugel Inc.
Glabellar Frown Lines Market Report Outlook 2032 | Allergan, Galderma, Merz Phar …
DelveInsight's "Glabellar Frown Lines Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Glabellar Frown Lines, historical and forecasted epidemiology as well as the Glabellar Frown Lines market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Glabellar Frown Lines market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted

All 5 Releases


More Releases for Schizophrenia

Schizophrenia Treatment Market Volume Analysis 2016-2026
Schizophrenia is a chronic mental disorder, characterized by poor emotional responses, breakdown of thinking and lack of social and physical motivation. The prominent causes of the disease include genetic malignancies, neuro-trauma, shocking incidence in life, drug and alcohol abuse and many others. Schizophrenia is a serious disorder which affects how a person thinks, feels and acts. Successful treatment for schizophrenia aims to relieve current symptoms, prevent future psychotic episodes and
Schizophrenia Treatment Market size and forecast-2026
Schizophrenia is a chronic mental disorder, characterized by poor emotional responses, breakdown of thinking and lack of social and physical motivation. The prominent causes of the disease include genetic malignancies, neuro-trauma, shocking incidence in life, drug and alcohol abuse and many others. Schizophrenia is a serious disorder which affects how a person thinks, feels and acts. Successful treatment for schizophrenia aims to relieve current symptoms, prevent future psychotic episodes and
Technological Advancements to Influence Schizophrenia Treatment Market Growth
Schizophrenia is a chronic mental disorder, characterized by poor emotional responses, breakdown of thinking and lack of social and physical motivation. The prominent causes of the disease include genetic malignancies, neuro-trauma, shocking incidence in life, drug and alcohol abuse and many others. Schizophrenia is a serious disorder which affects how a person thinks, feels and acts. Successful treatment for schizophrenia aims to relieve current symptoms, prevent future psychotic episodes and
Schizophrenia Drug Market & Pipeline Insight
Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could
Global Schizophrenia Drug Market Research Report 2017
Qyresearchreports include new market research report "Schizophrenia Drug" to its huge collection of research reports. The report on the Schizophrenia Drug deals with the all its critical facts and figures that will help in creating an in-depth and insightful analysis. The market is elucidated in a holistic fashion that allows the users to gain a thorough analysis of the market, as developed using the factors that are likely to have a
Schizophrenia Drug Market Trends To 2022
Global Schizophrenia Drug Industry 2021 Market Research Report analyzed the current state in the definitions, classifications, applications and industry chain structure. The report also focuses on the development trends as well as history, competitive landscape analysis, and key regions etc in the international markets. Global Schizophrenia Drug Industry 2021 Market Research Report is a professionally prepared report comprising of in-depth information as well as knowledge which is helpful to the new